Publications by authors named "A L Uss"
Introduction: Among the high risk groups, patients with multiple myeloma (MM) have one of the highest incidence of invasive pneumococcal disease, mainly pneumonias. Recent changes in MM treatment have now led to an increase of survival, while the infection-related mortality remains high. The question of efficacy of pneumococcal vaccination in patients receiving novel target agents has not been clinically investigated before.
View Article and Find Full Text PDFInvasive fungal infections are a major threat to a large cohort of immunocompromised patients, including patients with chemotherapy-associated neutropenia. Early differential diagnosis with bacterial infections is often complicated, which leads to a delay in empirical antifungal therapy and increases risk for adverse outcome. Accessibility and performance of specific fungal antigen and PCR-tests are still limited, while sepsis biomarkers are more broadly used in most settings currently.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the use of oral colistin to eradicate multidrug-resistant (MDR) and extensively drug-resistant (XDR) gram-negative bacteria from the intestines of patients with blood cancers undergoing chemotherapy.
- Patients receiving colistin showed a higher short-term success rate in decolonization compared to those not treated, and fewer developed bloodstream infections (BSI) within 30 days post-treatment.
- However, the long-term benefits were less clear, as the colonization rates and BSI risk were similar to the control group after 90 days, indicating that while colistin may help in the short run, it does not provide lasting protection.
Objectives: PALG CLL4 is the first, randomized, phase IIIb study with rituximab, cladribine, and cyclophosphamide (RCC) induction and subsequent maintenance with rituximab in previously untreated chronic lymphocytic leukemia (CLL) patients.
Methods: The induction treatment consisted of 6 RCC cycles regimen. Patients with complete response (CR) or partial response (PR) after an induction phase were randomized into a maintenance arm with rituximab or an observational arm.